These data implicate that the use of anti-PD-L1 antibodies in CCA will primarily modulate the functionality of CTLs rather than block the interaction between PD-1/PD-L1 on CTL and tumor cells. The gene discussed is CD274; the disease is cholangiocarcinoma.